[{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Fairmount","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Jade Biosciences Launches with $80M to Develop Therapies for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"Jade Biosciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Jade Biosciences \/ Fairmount","highestDevelopmentStatusID":"13","companyTruncated":"Jade Biosciences \/ Fairmount"}]

Find Clinical Drug Pipeline Developments & Deals by Jade Biosciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : The funding will be used to support Jade's plans to develop targeted therapies for indications with high unmet need across inflammation and immunology.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 01, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Discovery

                          Sponsor : Fairmount

                          Deal Size : $80.0 million

                          Deal Type : Financing

                          blank